SML3704

MRE-269

≥98% (HPLC)

• Synonym(e): 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid, ACT-333679, MRE 269, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid
• Empirische Formel (Hill-System): C₂₅H₂₉N₃O₃
• CAS-Nummer: 475085-57-5
• Molekulargewicht: 419.52
• MDL-Nummer: MFCD11976884
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: , White to light brown
• Löslichkeit: DMSO: 2 mg/mL, clear (Warmed)
• Lagertemp.: -10 to -25°C
• SMILES String: N(C(C)C)(CCCCOCC(=O)O)c1nc(c(nc1)c3ccccc3)c2ccccc2
• InChI: 1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
• InChIKey: OJQMKCBWYCWFPU-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

MRE-269 (ACT-333679) is an active form of Selexipag (NS-304). MRE-269 is a potent and highly selective IP receptor agonist (selective PGI2 receptor agonist).

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable